Introduction: Obesity is associated with numerous health problems, particularly metabolic and cardiovascular complications. This study aimed to assess the effects that, nine months of pharmacological intervention with orlistat or sibutramine, on obese Malaysians' body weight and compositions, metabolic profiles and inflammatory marker.
Introduction
The prevalence of obesity has increased globally at an alarming rate and is now considered an epidemic. Ac- internationally. In Malaysia, the values were higher, with 44% of adults being overweight and 14% of adults being obese, respectively 1 . Obesity is a known risk factor for flame through macrophage stimulation 3 . This leads to the release of free fatty acids (FFAs) into the circulatory system, decreased insulin sensitivity and abnormal release of inflammatory adipokines such as leptin, interleukin 6 (IL-6), tumour necrosis factor α (TNF-α), plasminogen activator inhibitor-1 (PAI-1) and monocyte chemoattractant protein-1 4, 5 . The release of adiponectin, a protective adipokine, also decreases with obesity 6 . Many hope that weight loss can reduce some of these metabolic and inflammatory profiles, potentially diminishing the rates of metabolic and cardiovascular risks in obese subjects. In this study, orlistat and sibutramine were used to reduce the weights of obese adults. Orlistat, a gastrointestinal lipase inhibitor, reduces fat absorption, while sibutramine, a monoamine-reuptake inhibitor, acts to reduce satiety 7 .
We previously reported that microvascular endothelial function was impaired in relatively young subjects who were obese; this finding was associated with increased hs-CRP, white blood cell count and serum triglyceride (TG), higher blood pressure (BP), decreased adiponectin and lower high density lipoprotein cholesterol (HDL-C) 8 .
After nine months of treatment with orlistat, significant improvements in systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), serum total cholesterol (TC) and microvascular endothelial dependent vasodilatation were observed 9 . The improvement in SBP, DBP and HR in this group may be through reduction in the activities of sympathetic nervous system (SNS) and rennin-angiotensin-aldosterone system (RAS), since obesity is associated with high blood pressure that is probably contributed by the activation of SNS and RAS 10, 11 .
Meanwhile, in the sibutramine-treated group of the same study, HR was significantly increased, although no significant changes were seen in BP and microvascular endothelial function. This could be expected, as sibutramine is a selective serotonin, norepinephrine and dopamine reuptake inhibitor, which increases the concentration of these neurotransmitters in the sympathetic synapses.
Currently, there are a lack of reports that compare the effects of orlistat and sibutramine simultaneously in a study on inflammatory and metabolic markers that include fasting insulin level, resistance and sensitivity. In the present study, we focused on the effects that nine months of orlistat-and sibutramine-based treatments had on the metabolic profiles and inflammatory markers (which include adiponectin, FPG, insulin resistance and hs-CRP) of obese Malaysian subjects.
Materials and Methods

Study Design and Subjects
A randomized controlled trial was conducted to examine the effects of orlistat and sibutramine on anthropome- Helsinki. All subjects signed an informed consent form before any of the study's procedures were performed.
One hundred and fifty obese subjects with body mass indexes of ! 27 kg/m 2 were screened 12 , and a total of 76 subjects were recruited. Subjects were randomly placed into two groups. The first group received three daily 120 mg dosages of orlistat for nine months (n=39), and the second group received a once daily 10 or 15 mg dosage of sibutramine for nine months (n=37). Random allocation into the intervention groups was determined using a computer-generated randomization list, and the study was completed before sibutramine was withdrawn from the market in Malaysia. Subjects included in this study were aged between 18 65 years old, normotensive or controlled hypertensive, had serum low density lipoprotein-cholesterol (LDL-C) <5 mmol/L, were nondiabetic (FPG <6.1 mmol/L) and non-smokers. Subjects with serious acute or chronic diseases such as coronary artery diseases, stroke, or active psychiatric conditions were excluded.
All subjects received healthy lifestyle counselling that included instructions on proper diet and exercise. All patients had at least four consultations with at least one of two of the study's dieticians. Written instructions containing advice on how to increase physical activity were provided; this advice was reinforced every time the patients visited the clinic or attended follow-up examinations with one of the dieticians.
Measurements
Body weight and height were measured using a digital weighing scale (SECA 789, Hamburg, Germany) with an Indicates significant difference for baseline characteristics between the 2 groups using independent t-test (P=0.009) *P<0.05, **P<0.01, ***P<0.001: within group significant effects of time on 9 months intervention using repeated measures ANOVA § Indicates significant difference on 9 months intervention between the 2 groups using repeated measures ANOVA (P=0.026) attached stadiometer (SECA 245, Hamburg, Germany). HOMA%B (pancreatic B cell secretory capacity) were measured using HOMA software 13 . HOMA-IR (insulin resistance) parameters were calculated manually using the following formula: HOMA-IR = (fasting insulin in μIU/ ml X fasting glucose in mmol/L)/22.5 14 .
Follow-up visits were performed at the sixth and ninths months of intervention, wherein blood measurements and other study parameters were repeated. Drug compliance was determined by counting pills, and any side effects that occurred during treatment were investigated during patient visits.
Statistical Analysis
Statistical analyses were performed using the Statistical 
Results
Seventy-six obese subjects were randomly assigned to take either orlistat (n=39) or sibutramine (n=37).
Throughout the nine month intervention, there were 15 dropouts in the orlistat-treated group and 13 dropouts in the sibutramine-treated group, resulting in a total of 24 subjects that completed the intervention in each group.
Among the causes of dropouts were pregnancy, drug interaction, failure to attend follow-up examinations and non-compliance with the study's medication. Table 1 shows the value of anthropometrics, body composition, FPG, HOMA%B and HOMA-IR at baseline Fig. 1 hsCRP, adiponectin, fasting insulin and insulin sensitivity (HOMA%S) levels at baseline, 6 and 9 months of intervention with orlistat and sibutraminê Indicates significant difference for baseline characteristics between the 2 groups using independent t-test (Fasting insulin, P=0.013; HOMA%S, P=0.011) *P<0.05, **P<0.01, ***P<0.001: within group significant effects of time on 9 months intervention using repeated measures ANOVA Error bars represent standard deviations of the means and during the six and nine month treatments of the orlistat-(n=24) and sibutramine-treated groups (n=24).
There were no significant differences between the two groups in their baseline weight, BMI, WC, BF, VF, FPG and HOMA%B. However, HOMA%S was significantly higher in the sibutramine-treated group (P=0.011) (Fig.   1) . HOMA-IR (P=0.009) ( Table 1 ) and baseline fasting insulin (P=0.013) (Fig. 1) were significantly higher in orlistat-treated group.
After nine months treatment for both groups, weight, BMI, WC, BF and VF were significantly lower at the end of the nine month intervention. By contrast, FPG was significantly lower at the end of the nine month intervention for the orlistat-treated group. After the nine month intervention, the orlistat-treated group achieved an average weight loss of 5.58%, while the sibutramine-treated group achieved an average weight loss of 4.54% (Table   1) . While hs-CRP was significantly lower at the end of the intervention period, adiponectin was significantly higher for both groups at the end of the intervention period (Fig. 1) .
While HOMA-IR was significantly lower for both groups at the end of the nine months intervention ( Table   1) , HOMA%S was significantly higher for both groups at the end of the nine month intervention (Fig. 1) . Serum fasting insulin and HOMA%B were significantly lower for the sibutramine-treated group ( Table 1 ). In addition, except for FPG (P=0.026), there was no significant difference observed in the changes of weight, anthropometry, body composition, metabolic profile and hsCRP between both groups during the nine months treatment period ( Table 1) .
Discussion
After nine months of orlistat and sibutramine intervention, significant reductions in weight, BMI, WC, BF, and VF were seen in both the study's groups; there were no significant differences between both groups in these reductions. A significant reduction in hs-CRP levels and a significant increase in adiponectin levels were also observed in both groups with no significant differences between groups. Likewise, significant increases in HOMA%S and significant reductions (or improvements) in HOMA-IR were recorded in each group. Finally, while FPG significantly decreased in the orlistat-treated group, fasting insulin and HOMA%B significantly decreased in the sibutramine-treated group.
Anthropometrics and Body Composition
After nine months treatment, both the orlistat-and sibutramine-treated groups achieved significant reductions in their weight, BMI, WC, BF and VF. The orlistattreated group achieved a 5.58% average weight loss, and the sibutramine-treated group achieved a 4.54% average weight loss. In the orlistat-treated group, 58.3% of the subjects reached a ! 5% weight loss after nine months of therapy, and in the sibutramine-treated group, 50% of the subjects reached a ! 5% weight loss after nine months of therapy. It was reported that a minimum weight loss of 5% is required to reduce visceral and subcutaneous fat in obese subjects and to improve their levels of glucose, insulin, adiponectin, leptin and hs-CRP 15 . Supporting our findings, previous studies showed significant improvement of body weight, BMI, BF, VF and WC after orlistat or sibutramine therapy 16, 17 . Furthermore, mean weight loss among our subjects was 4.62 kg and 3.84 kg respectively for orlistat and sibutramine treated groups. Similarly, in previous meta-analysis, weight loss with orlistat treatment has ranged between 2.5 and 3.2 kg, and for sibutramine-treated patients, between 3.6 and 4.7 kg 18 .
Our study did not show significant differences in the reductions of weight, BMI, WC, BF and VF between the two groups; similar findings have been reported in an existing multicentre clinical trial 19 .
Metabolic Profile
Both treatments caused elevations in serum adiponectin levels after nine months but there was no significant difference in the changes of adiponectin levels between the two groups throughout the nine months treatment.
The results in our study corroborate with evidence that has been supported in previous studies. For instance, studies found that the orlistat-and sibutramine-treated groups showed elevations of adiponectin levels and was associated with reduction in BMI and BF 17, 20 . In our study, the increase in adiponectin levels may have been due to weight loss. Adiponectin gene expression is increased by leanness and decreased by TNF-α and obesity 21 . There is a strong negative correlation between fat mass and concentration of plasma adiponectin . This improvement in insulin sensitivity was due to the fact that adiponectin stimulates glucose uptake and fatty acid oxidation in both adipose tissue and skeletal muscle 32, 33 , besides its function in suppressing the output of hepatic glucose 30 .
After nine months treatment, the orlistat-and sibutramine-treated groups showed an approximate 5% weight loss after nine months of intervention. This weight loss was associated with an increase in HOMA%S and a decrease in HOMA-IR. While FPG decreased significantly in the orlistat-treated group, no significant changes in FPG were recorded in the sibutramine-treated group. Fasting insulin and HOMA%B significantly decreased after the sibutramine treatment, and although some reduction was noted in the orlistat treatment, it did not reach statistical significance.
These findings concede with previous studies. For example, one study showed improvements of insulin sensitivity without significant changes in FPG after three months of sibutramine therapy 17 . Another study showed that the orlistat-treated group had higher reductions in BMI and greater reductions in HOMA-IR when compared to its placebo group 20 . Meanwhile, an existing meta-analysis has revealed that orlistat reduced FPG in four out of six of its studies, with no significant differences between FPG patients who were treated with sibutramine and FPG patients who were treated with a placebo 34 .
In the current study, there is possible explanation for the differences that orlistat and sibutramine therapies have on FPG responses. It may be due to the differences in HOMA-IR that both groups had at baseline. At baseline, insulin resistance was significantly higher in the orlistat-treated group than it was for the sibutraminetreated group. Reduction in insulin resistance appears greater for the orlistat-treated group, although not significantly, which may have contributed to the group's more significant reduction in FPG. Findings in the current study are dissimilar to those in previous studies 35 .
Following a nine-month long intervention with a once daily 10 or 15 mg dosage of sibutramine, combined with a low-caloric diet for six months, sibutramine-treated patients experienced a mean weight loss of 4.54%. This weight loss was associated with a significant rise in serum adiponectin and significant improvements in FPG and insulin sensitivity. By contrast, no significant improvement in these parameters was observed in the orlistat-treated group. This discrepancy may be explained by the fact that weight loss in the orlistat-treated group was small (2.5%) and did not reach the minimum 5% from baseline. Minimum weight loss of 5% may be required to improve metabolic markers such as leptin, hs-CRP, adiponectin and glucose and insulin levels; it may also reduce visceral and subcutaneous fat in obese sub- Therefore, the higher the HOMA%S, the lower the HOMA-IR and HOMA%B.
Hs-CRP
In this study, both orlistat and sibutramine caused significant decreases in serum hs-CRP. Conversely, there were no significant differences between each group's serum hs-CRP levels. The results in our study corroborate with evidence that has been supported in previous studies. Researchers have reported that orlistat and sibutramine treatment caused significant reduction in hs-CRP levels 16, 20, 35 and this reduction was associated with reduction in BMI and BF
18
.
Hs-CRP is an independent risk factor for cardiovascular diseases such as stroke, coronary artery disease, myocardial infarction and peripheral artery disease while its presence in atherosclerotic lesions has been demonstrated previously 36, 37 . Increased hs-CRP levels as well as its positive correlation with obesity indices such as weight, BMI, WC, BF and VF have been previously reported in obese subjects 8, 29 . Hs-CRP levels were also reported to be strongly correlated with the severity of obesity and central obesity 38 . This indicates that obesity is associated with a low-grade inflammatory state. Significant weight loss of 5.58% and 4.54% in the orlistat-and sibutraminetreated groups, respectively, could be a main contributor towards the reduction of hs-CRP levels. While weight reductions of 2.5% with orlistat were reported to cause no changes in CRP levels, CRP levels did fall after the 5.4%
weight reduction in sibutramine-treated subjects 35 . Even without pharmaceutical aid, significant decreases in CRP levels can be achieved as long as there are significant reductions in weight 39 . These findings, which have been supported by evidence that hs-CRP is positively associated with obesity 29, 38 , suggest that hs-CRP levels are due in part to their production in adipose tissue. It can therefore be presumed that weight loss causes decreases in hs-CRP levels, as well.
During the study, some gastrointestinal side effects such as oily spotting, flatulence with discharge, fecal urgency, oily stool and increased defecation had been reported with orlistat-treated group. This is probably due to orlistat mechanism of action, where there is likely to be a higher presence of fat in the intestine as a result of reduction in fat absorption due to lipase enzyme inhibition. Nausea, insomnia, dry mouth, constipation, headache, altered taste had been reported by a few subjects in sibutramine-treated group. However, these side effects were considered minor and tolerable by our subjects; advices on reducing and preventing these adverse effects were given to our subjects which helped in ameliorating most of these side effects. None of our study subjects requested to withdraw from this study due to these side effects. Among the advices given include, taking less fatty food in the orlistat-treated group. For sibutramine group, advices given include increasing intake of fibre and fluids to avoid constipation, as well as taking sibutramine early in the morning to minimize insomnia.
In our opinion, improvement in the parameters reported here namely visceral fat, adiponectin, hsCRP, fasting insulin level, sensitivity and resistance, were likely due to significant body weight reduction; however, this study cannot confirm this suggestion. Both drugs reduced weight significantly without significant difference between them, and similarly, both drugs improved the above parameters without significant difference between them. Orlistat and sibutramine may contribute in improving these parameters indirectly via their effect on reducing body weight. A few lifestyle modification studies without pharmaceutical interventional had also shown that improvement in certain metabolic and inflammatory profile among overweight and obese subjects can occur with significant weight loss. For example, a study by Ariffin et al. 40 had shown that nine months education on modified lifestyle intervention (by increasing physical activity and modifying diet) improved insulin sensitivity and resistance, reduced hs-CRP. Esposito et al. 39 reported that through low-energy diet and increased physical activity, there were reductions in body weight, BMI, waist circumference, CRP, fasting insulin and increment in adiponectin.
We conclude that nine months of orlistat-and sibutramine-based treatment significantly reduced weight that was associated with reductions in body and visceral fat, fasting insulin levels and resistance, hs-CRP and higher insulin sensitivity and levels of adiponectin. Improvements in anthropometric, body composition, adiponectin, insulin level and resistance and inflammatory
were not significantly different between the orlistat-and sibutramine-treated groups. This suggests that, by reducing weight, both orlistat and sibutramine can effectively help manage obesity and reduce the metabolic and cardiovascular risks associated with obesity.
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